Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Talha Munir, Jake Emmerson, Anna Hockaday, Jamie B Oughton, Dena Howard, David Phillips, Jeff Neilson, Nicholas Pemberton, Shankara Paneesha, Ben Kennedy, Andy Rawstron, Peter Hillmen
The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II/III trial designed to test whether consolidation with obinutuzumab is safe and eradicates minimal residual disease (MRD) and, subsequently, whether this leads to prolonged progression-free survival (PFS) in patients with CLL who have recently responded to chemo-immunotherapy. Patients with a response 3-24 months after chemotherapy were assessed for MRD. MRD-positive patients were randomised to receive consolidation therapy with obinutuzumab or no consolidation...
August 26, 2022: British Journal of Haematology
#22
REVIEW
Andrew Davies, Arnon P Kater, Jeff P Sharman, Stephan Stilgenbauer, Umberto Vitolo, Christian Klein, Joana Parreira, Gilles Salles
The type II anti-CD20 antibody obinutuzumab has structural and mechanistic features that distinguish it from the first anti-CD20 antibody, rituximab, which have translated into improved efficacy in phase III trials in indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). These gains have been shown through improvements in, and/or increased durability of, tumor response, and increases in progression-free survival in patients with CLL or follicular lymphoma (FL). Ongoing research is focusing on the use of biomarkers and the development of chemotherapy-free regimens involving obinutuzumab...
August 2022: Future Oncology
#23
JOURNAL ARTICLE
Sara Ilari, Patrizia Russo, Stefania Proietti, Laura Vitiello, Carolina Muscoli, Carlo Tomino, Mirta Milic, Stefano Bonassi
Oxidative stress that leads to oxidatively damaged DNA, plays a crucial role in chronic obstructive pulmonary disease (COPD) as well as in the onset of neurodegenerative diseases. The consequent genomic instability is the first neuropathological event found in the preclinical phase of cognitive impairment (CI), and the level of DNA damage is closely related to the degree of dementia. Since CI has been associated with COPD, we investigated the extent of DNA damage in isolated lymphocytes with the Comet assay, in a group of severe COPD patients with cognitive function measured by the Mini-Mental State Examination (MMSE)...
June 2022: Mutation Research. Genetic Toxicology and Environmental Mutagenesis
#24
JOURNAL ARTICLE
Kirollos S Hanna, Andrew Fijalka, Ian Watson, Olivia Brown, Apiew Ojulu
OBJECTIVE: Chronic lymphocytic leukemia and small lymphocytic lymphoma remain the most prevalent adult leukemia in Western countries. Novel therapeutics have established long-term efficacy and have changed the landscape in patient management. In contrast, novel approaches pose opportunities for patients to be treated for finite durations. In this manuscript, we highlight long-term safety and efficacy data with Bruton's tyrosine kinase inhibitors and combination BCL2 + anti-CD20 therapies...
May 30, 2022: Journal of Oncology Pharmacy Practice
#25
JOURNAL ARTICLE
Alexander Biederstädt, Katayoun Rezvani
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for patients with high-risk acute leukemias, but unfortunately disease recurrence remains the major cause of death in these patients. Infusion of donor lymphocytes (DLI) has the potential to restore graft-versus-leukemia immunologic surveillance; however, efficacy varies across different hematologic entities. Although relapsed chronic myeloid leukemia, transplanted in chronic phase, has proven remarkably susceptible to DLI, response rates are more modest for relapsed acute myeloid leukemia and acute lymphoblastic leukemia...
January 5, 2023: Blood
#26
JOURNAL ARTICLE
Daobin Zhou, Wei Xu, Hongbing Ma, Chunting Zhao, Yu Hu, Yaozhong Zhao, Depei Wu, Xielan Zhao, Yanjuan He, Jinsong Yan, Chunsen Wang, Fanyi Meng, Jie Jin, Xiaohong Zhang, Kang Yu, Jianda Hu, Yue Lv
BACKGROUND: Chronic lymphoblastic leukemia (CLL) is the most common adult leukemia and mainly affects the elderly. Chemoimmunotherapy still has a role in the standard frontline therapy for specific population. However, the clinical activity of bendamustine has not been investigated in unfit Chinese patients with CLL. This study aimed to compare the efficacy and safety of bendamustine versus chlorambucil for untreated Chinese patients with Binet stage B/C CLL. METHODS: In this multi-center, randomized, open-label, parallel-controlled, phase III trial, patients with previously untreated CLL were enrolled and randomly assigned (1:1) to receive bendamustine or chlorambucil...
January 15, 2022: Investigational New Drugs
#27
REVIEW
Jie Wang, Idan Goren, Bo Yang, Sinan Lin, Jiannan Li, Michael Elias, Claudio Fiocchi, Florian Rieder
BACKGROUND: Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis. Additional S1PR modulators are being tested in clinical development programmes for both ulcerative colitis and Crohn's disease. AIM: To provide an overview of advances in understanding S1PRs biology and summarise preclinical and clinical investigations of S1P receptor modulators in chronic inflammatory disease with special emphasis on inflammatory bowel diseases (IBD)...
February 2022: Alimentary Pharmacology & Therapeutics
#28
REVIEW
Edgar Carnero Contentti, Jorge Correale
Neuromyelitis optica (NMO) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by acute optic neuritis (ON) and transverse myelitis (TM). NMO is caused by a pathogenic serum IgG antibody against the water channel aquoporin 4 (AQP4) in the majority of patients. AQP4-antibody (AQP4-ab) presence is highly specific, and differentiates NMO from multiple sclerosis. It binds to AQP4 channels on astrocytes, triggering activation of the classical complement cascade, causing granulocyte, eosinophil, and lymphocyte infiltration, culminating in injury first to astrocyte, then oligodendrocytes followed by demyelination and neuronal loss...
September 16, 2021: Journal of Neuroinflammation
#29
MULTICENTER STUDY
[Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
Souichi Shiratori
Graft versus host disease (GVHD) prophylaxis using antithymocyte globulin (ATG) has been shown for chronic GVHD inhibition effect by a series of randomized control trials in unrelated hematopoietic or peripheral blood stem cell transplantation (PBSCT). Lower doses of ATG have been used in recent studies, although the optimal dose of ATG remains undefined. Consequently, a multicenter phase II study of low-dose ATG (2 mg/kg Thymoglobulin® ) was conducted in patients undergoing human leukocyte antigen-matched PBSCT, showing the safety and efficacy for the prevention of both acute and chronic GVHD...
2021: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
#30
JOURNAL ARTICLE
(no author information available yet)
In a phase III trial comparing acalabrutinib with ibrutinib in patients with previously treated chronic lymphocytic leukemia, researchers found that progression-free survival for the two BTK inhibitors was the same. However, acalabrutinib proved to be better tolerated, perhaps due to its greater selectivity.
October 2021: Cancer Discovery
#31
JOURNAL ARTICLE
Matthew C Cheung, Nicole Mittmann, Carolyn Owen, Nizar Abdel-Samad, Graeme A M Fraser, Selay Lam, Michael Crump, Catherine Sperlich, Richard van der Jagt, Anca Prica, Stephen Couban, Jennifer A Woyach, Amy S Ruppert, Allison M Booth, Sumithra J Mandrekar, Gail McDonald, Lois E Shepherd, Hope Yen, Bingshu E Chen, Annette E Hay
INTRODUCTION: The Alliance A041202/CCTG CLC.2 trial demonstrated superior progression-free survival with ibrutinib-based therapy compared to chemoimmunotherapy with bendamustine-rituximab (BR) in previously untreated older patients with chronic lymphocytic leukemia. We completed a prospective trial-based economic analysis of Canadian patients to study the direct medical costs and quality-adjusted benefit associated with these therapies. METHODS: Mean survival was calculated using the restricted mean survival method from randomization to the study time-horizon of 24 months...
July 3, 2021: Clinical Lymphoma, Myeloma & Leukemia
#32
RANDOMIZED CONTROLLED TRIAL
John C Byrd, Peter Hillmen, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL). METHODS: Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity...
November 1, 2021: Journal of Clinical Oncology
#33
REVIEW
A Blackmon, S O'Brien
Acalabrutinib was approved by the U.S. Food and Drug Administration (FDA) for treatment-naive (TN) and relapsed/refractory (R/R) use for patients with chronic lymphocytic leukemia (CLL) in November 2019 following the phase III ASCEND and ELEVATE-TN registration trials. Acalabrutinib is a second-generation Bruton tyrosine kinase inhibitor (BTKi) that was developed after ibrutinib, the first-in-class BTKi. Ibrutinib is usually well tolerated and provides durable remissions; however, some patients experience toxicities from the off-target effects that lead to treatment discontinuation...
July 2021: Drugs of Today
#34
JOURNAL ARTICLE
Karina Aivazian, Tasnia Ahmed, Mary-Ann El Sharouni, Jonathan R Stretch, Robyn P M Saw, Andrew J Spillane, Kerwin F Shannon, Sydney Ch'ng, Omgo E Nieweg, John F Thompson, Serigne N Lo, Richard A Scolyer
Regression in melanoma is an immunological phenomenon that results in partial or complete replacement of the tumor with variably vascular fibrous tissue, often accompanied by pigment-laden macrophages and chronic inflammation. In some cases, tumor-infiltrating lymphocytes (TILs) may represent the earliest phase of this process. The prognostic significance of regression has long been a matter of debate, with inconsistent findings reported in the literature to date. This study sought to determine whether regression in primary cutaneous melanomas predicted sentinel lymph node (SLN) status and survival outcomes in a large cohort of patients managed at a single centre...
November 2021: Modern Pathology
#35
REVIEW
Lukáš Smolej, Pavel Vodárek, Dominika Écsiová, Martin Šimkovič
The paradigm of first-line treatment of chronic lymphocytic leukaemia (CLL) is currently undergoing a radical change. On the basis of several randomised phase III trials showing prolongation of progression-free survival, chemoimmunotherapy is being replaced by treatment based on novel, orally available targeted inhibitors such as Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib or bcl-2 inhibitor venetoclax. However, the use of these agents may be associated with other disadvantages. First, with the exception of one trial in younger/fit patients, no studies have so far demonstrated benefit regarding the ultimate endpoint of overall survival...
June 23, 2021: Cancers
#36
JOURNAL ARTICLE
Alessandra Picardi, Nicoletta Sacchi, Valeria Miotti, Francesca Lorentino, Elena Oldani, Alessandro Rambaldi, Mariarosaria Sessa, Benedetto Bruno, Michela Cerno, Luca Vago, Paolo Bernasconi, William Arcese, Fabio Benedetti, Pietro Pioltelli, Domenico Russo, Lucia Farina, Franca Fagioli, Stefano Guidi, Giorgia Saporiti, Francesco Zallio, Patrizia Chiusolo, Carlo Borghero, Gabriele Papalinetti, Ursula La Rocca, Giuseppe Milone, Teresa Lamparelli, Angelo M Carella, Mario Luppi, Attilio Olivieri, Massimo Martino, Paola Carluccio, Ivana Celeghini, Marco Andreani, Anna M Gallina, Francesca Patriarca, Simona Pollichieni, Sonia Mammoliti, Silvia Miccichè, Ilaria Mangione, Fabio Ciceri, Francesca Bonifazi
HLA molecules are important for immunoreactivity in allogeneic hematopoietic stem cell transplantation (HSCT). The Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti promoted a retrospective observational study to evaluate HLA matching and the impact of allelic HLA mismatching and non-HLA factors on unrelated Italian HSCT outcomes. From 2012 to 2015, 1788 patients were enrolled in the study...
May 2021: Transplantation and cellular therapy
#37
REVIEW
Ranjithkumar Rajendran, Gregor Böttiger, Christine Stadelmann, Srikanth Karnati, Martin Berghoff
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) affecting more than two million people worldwide. In MS, oligodendrocytes and myelin sheaths are destroyed by autoimmune-mediated inflammation, while remyelination is impaired. Recent investigations of post-mortem tissue suggest that Fibroblast growth factor (FGF) signaling may regulate inflammation and myelination in MS. FGF2 expression seems to correlate positively with macrophages/microglia and negatively with myelination; FGF1 was suggested to promote remyelination...
April 13, 2021: Cells
#38
JOURNAL ARTICLE
Melhem M Solh, Gabriel Hinojosa, Justin Laporte, Scott R Solomon, Lawrence E Morris, Xu Zhang, H Kent Holland, Asad Bashey
T-replete haploidentical donor transplants using posttransplant cyclophosphamide (haplo) have greatly expanded donor availability and are increasingly utilized. Haplo were originally performed using truly nonmyeloablative conditioning and a bone marrow graft. We have also developed myeloablative conditioning and peripheral blood stem cell (PBSC) grafts for use with haplo. However, some patients may not tolerate myeloablative conditioning but may still benefit from a more dose-intensified preparative regimen to control malignancy and diminish graft rejection...
2021: Advances in Hematology
#39
REVIEW
Max J Gordon, Alexey V Danilov
Ibrutinib, the first in class of the oral covalent Bruton tyrosine kinase (BTK) inhibitors, has profoundly changed the treatment landscape of chronic lymphocytic leukemia (CLL). The phase III RESONATE and RESONATE-2 trials first demonstrated the superiority of ibrutinib over ofatumumab in the relapsed/refractory setting and over chlorambucil in older patients with de novo disease. The phase III ECOG-ACRIN trial extended these results to young, fit patients, demonstrating a significant survival advantage to ibrutinib plus rituximab over fludarabine, cyclophosphamide, and rituximab...
2021: Therapeutic Advances in Hematology
#40
MULTICENTER STUDY
John C Byrd, Jennifer A Woyach, Richard R Furman, Peter Martin, Susan O'Brien, Jennifer R Brown, Deborah M Stephens, Jacqueline C Barrientos, Stephen Devereux, Peter Hillmen, John M Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G Wierda
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). Adults were eligible for enrollment if chemotherapy was declined or deemed inappropriate due to comorbidities (N = 99). Patients had a median age of 64 years and 47% had Rai stage III/IV disease. Acalabrutinib was administered orally 200 mg once daily, or 100 mg twice daily until progression or intolerance...
June 17, 2021: Blood
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
